newsfilter
← Latest News
PR Newswire·

RVL Pharmaceuticals plc Announces Preliminary Second Quarter 2022 UPNEEQ® Net Product Sales Results

-- Expects second quarter 2022 preliminary UPNEEQ net product sales of approximately $8.4 million, representing an increase of 42% from the first quarter 2022 -- -- Second quarter 2022 net product sales growth contributes to approximately $14.4 mil